$STE (Steris Plc)

$STE {{ '2015-12-22T12:29:02+0000' | timeago}} • Announcement

$STE said it has completed the acquisition of Synergy Health on Nov. 2, 2015 and beginning of 3Q16 the combined company will report under 4 business segments, namely Healthcare Products, Healthcare Specialty Services, Applied Sterilization Technologies & Life Sciences.

$XRAY {{ '2018-01-17T20:31:22+0000' | timeago}} • Announcement

$XRAY's BoD has appointed Donald M. Casey Jr. as CEO and board member of the company, effective Feb. 12, 2018. Casey succeeds Mark A. Thierer, who served as Interim CEO since Sept. 28, 2017.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$KAMN {{ '2018-01-16T17:22:14+0000' | timeago}} • Announcement

$KAMN said its Aerospace segment received a contract modification in excess of $17MM for the procurement of Joint Programmable Fuzes. The award is an additional order under Option 13 of the JPF contract with the US Air Force. The modification increases the total value of Option 13 to more than $102MM, all of which was in backlog at Dec. 31, 2017.

$KAMN {{ '2018-01-10T19:21:07+0000' | timeago}} • Announcement

$KAMN announced that Rebecca F. Stath has been appointed to serve as Assistant Vice President, SEC Compliance and External Reporting, reporting to John J. Tedone, Vice President, Finance and Chief Accounting Officer.

$KAMN {{ '2018-01-10T19:16:01+0000' | timeago}} • Announcement

$KAMN announced that Amanda N. Balboni has been appointed to serve as Assistant Vice President, Internal Audit. Ms. Balboni has previously worked at Coburn Technologies, Stanley Black & Decker and PricewaterhouseCoopers.

$PII {{ '2018-01-09T19:13:23+0000' | timeago}} • Announcement

$PII named Lucy Clark Dougherty as its SVP, General Counsel, Compliance Officer and Corporate Secretary, reporting to Chairman and CEO Scott Wine effective Jan. 29, 2018. Dougherty will also serve as president of the Polaris Foundation.

$HRC {{ '2018-01-09T17:07:14+0000' | timeago}} • Announcement

$HRC announced its preliminary 1Q18 revenue. For this period, the company expects worldwide revenue of approx $670MM, an increase of 5% YoY. Core revenue increased approx 2%, exceeding the company's previously issued guidance of flat core revenue growth.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$IART {{ '2018-01-08T12:15:32+0000' | timeago}} • Announcement

$IART said it expects 4Q17 revenue to be approx $365MM, an increase of over 40% compared to 4Q16, helped by Derma Sciences and Codman Neurosurgery acquisitions. The results will be announced in late February, 2018.

$IDXX {{ '2018-01-05T12:52:03+0000' | timeago}} • Announcement

$IDXX expects the recently passed Tax Cuts and Jobs Act to benefit the company by reducing its recurring effective tax rate beginning in 2018, by approx 750-850 bps. It also estimates that the enactment of the tax legislation will result in a one-time reduction of about $35-45MM in earnings for 4Q17 and FY17.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

$XRAY {{ '2017-12-13T11:58:34+0000' | timeago}} • Announcement

$XRAY BoD declared a quarterly cash dividend of $0.0875 per share of common stock.  The dividend is payable on Jan. 12, 2018 to holders of record on Dec. 29, 2017.

$AGN {{ '2017-12-12T19:58:45+0000' | timeago}} • Announcement

$AGN gets FDA clearance for the CoolSculpting, a treatment to improve the appearance of lax tissue in double chin. Allergan got this CoolSculpting technology by acquiring Zeltiq Aesthetics in Feb. 2017 for $2.4Bil. Allergan added that in an 18-week study, 77% of patients showed improved appearance in their lax tissue.

$AGN {{ '2017-12-12T19:07:05+0000' | timeago}} • Announcement

$AGN enters into a buyout deal with $RPRX through a cash tender offer of $0.67 per share, representing a 43% premium of Repros Therapeutics’ Dec. 11th closing price ($0.47). Allergan's subsidiary will acquire Repros, which focuses on developing the drugs for male and female reproductive disorders. The deal is expected to close in 1Q18.

$HLS {{ '2017-12-12T13:23:46+0000' | timeago}} • Announcement

$HLS appointed Nancy Schlichting as an independent director, effective Dec. 11, 2017. With this appointment, the Board will expand to 11 directors. Schlichting currently serves on the boards of $WBA and $HRC.

$JCI {{ '2017-12-11T16:43:09+0000' | timeago}} • Announcement

$JCI's BoD appointed John Young to serve as a director. Young is currently group president of $PFE Essential Health. Effective Jan. 1, 2018, he will become group president of Pfizer Innovative Health, which comprises six business groups focused on improving health through innovative products covering every stage of life.

Recent Transcripts

SCHN (Schnitzer Steel Industries, Inc.)
Tuesday, January 9 2018 - 4:30pm
SHLO (Shiloh Industries Inc.)
Friday, January 5 2018 - 1:00pm
RAD (Rite Aid Corporation)
Wednesday, January 3 2018 - 10:00pm
IMUC (ImmunoCellular Therapeutics, Ltd.)
Tuesday, November 21 2017 - 10:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
JCI (Johnson Controls Inc.)
Thursday, November 9 2017 - 4:00pm
SRCL (Stericycle, Inc.)
Wednesday, November 8 2017 - 10:01pm
IVC (Invacare Corporation)
Wednesday, November 8 2017 - 1:30pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
XRAY (DENTSPLY International Inc.)
Friday, November 3 2017 - 12:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
MTD (Mettler-Toledo International Inc.)
Thursday, November 2 2017 - 9:00pm
RTIX (RTI Surgical Inc.)
Thursday, November 2 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
WMGI (Wright Medical Group N.V.)
Wednesday, November 1 2017 - 8:30pm
STE (Steris Plc)
Wednesday, November 1 2017 - 2:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
MASI (Masimo Corporation)
Tuesday, October 31 2017 - 8:30pm
WCG (WellCare Health Plans, Inc.)
Tuesday, October 31 2017 - 1:30pm

AlphaGraphics you may like